威勝信息(688100.SH):2月中標千萬以上項目1個 中標金額總計約4215.45萬元
格隆匯3月1日丨威勝信息(688100.SH)公佈關於2022年2月中標合同情況,公司中標項目:國家電網有限公司2022年新增第三批採購(營銷新增批次電能表(含用電信息採集)招標採購)項目(中標金額4215.45萬元人民幣)。
以上項目中標金額總計為人民幣4215.45萬元,佔公司2021年度經審計的營業總收入的2.31%,以上項目項目已進行中標候選人公示,尚未與招標人簽訂相關正式合同,存在不確定性;具體交貨批次和時間受現場施工進度影響,對2022年當期業績影響存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.